Alliance Pharma PLC

Annual Report and Preliminary Results correction

RNS Number : 7825T
Alliance Pharma PLC
29 March 2021

For immediate release

  29 March 2021



("Alliance" or the "Group")


Annual Report and Accounts

and correction to FY2020 Preliminary Results



Alliance Pharma plc (AIM: APH) announces that the Annual Report and Accounts for the year ended 31 December 2020 are now available on the Group's website,  

Printed copies will be mailed on or before 9 April 2021 to those shareholders who have opted out of receiving electronic communications.

Printed copies will also be available from Buchanan and may be requested by e-mailing [email protected] or by telephoning 020 7466 5000.



Following release of the Group's preliminary results for the year ended 31 December 2020 on 23 March 2021, an error in the mathematical calculation of the weighted average number of Ordinary shares was identified.

The correct weighted average number of Ordinary shares for the 12 months ended 31 December 2020 for the Basic EPS calculation is 531,062,798, and not 521,686,254 as originally stated in the preliminary results on 23 March 2021. The correct weighted average number of Ordinary shares for the Diluted EPS calculation is 537,318,838 and not 527,924,294 as originally stated in the preliminary results announcement on 23 March 2021.

This increase in the number of shares results in a small reduction to EPS measures which are correctly stated as follows:

Year ended 31 December 2020


Correctly stated



As stated on 23 March 2021 (p)

Reported basic earnings per share



Reported diluted earnings per share



Underlying basic earnings per share



Underlying diluted earnings per share




The corrected numbers have been reflected in the Group's 2020 Annual Report and Accounts and in the version of the FY2020 preliminary results statement available on Alliance's website.

The detail of the EPS calculation is set out in note 10 of the Annual Report and Accounts.


For further information:


Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer


+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele

Corporate Broking: James Black


Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

Corporate Broking: Patrick Robb


About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.